Physician profile
Jennifer L Hill
NPI 1497035604
$334,607.44
in general payments reported to CMS, 2019-2025
39 companies · $65K in 2025
The $65K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $21K · 2021: $33K · 2022: $32K · 2023: $51K · 2024: $95K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $177K · Consulting Fee: $14K · Food and Beverage: $12K · Travel and Lodging: $8,323 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $177,178.57 |
| Consulting Fee | $13,899.43 |
| Food and Beverage | $11,532.41 |
| Travel and Lodging | $8,323.28 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $133,958.36 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $61,581.56 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $54,248.52 | 2019-2025 | Dupixent |
| Optinose US, INC. | $48,598.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $9,169.06 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $7,685.20 | 2019-2025 | |
| Amgen INC. | $7,454.86 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $4,566.15 | 2019-2025 | Xolair |
| Regeneron Pharmaceuticals, INC. | $3,198.00 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $694.45 | 2021-2025 | Cuvitru, Hyqvia, Takhzyro |
| Allerderm Laboratories | $500.00 | 2021 | |
| Pfizer INC. | $404.40 | 2019-2025 | |
| Blueprint Medicines Corporation | $317.38 | 2022-2023 | Ayvakit |
| Csl Behring | $258.11 | 2022-2025 | Hizentra |
| Pharming Healthcare, INC. | $219.28 | 2019-2025 | Ruconest |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $189.08 | 2019-2021 | |
| Cycle Pharmaceuticals INC | $180.76 | 2025 | Sajazir |
| Biocryst US Sales Co., LLC | $162.64 | 2021-2025 | Orladeyo |
| Incyte Corporation | $157.60 | 2021-2025 | Opzelura |
| Adma Biomanufacturing LLC | $143.26 | 2022-2025 | |
| Organon LLC | $142.36 | 2025 | Vtama |
| Grifols USA, LLC | $109.35 | 2019-2025 | Xembify |
| Kaleo, INC. | $102.48 | 2021-2024 | Auvi-Q |
| Octapharma USA, INC. | $94.16 | 2023-2024 | Panzyga, Cutaquig |
| Sanofi-Aventis U.S. LLC | $81.61 | 2019 | |
| Lilly USA, LLC | $75.84 | 2021-2025 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $52.13 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $51.34 | 2025 | Dawnzera |
| Shire North American Group INC | $33.39 | 2019 | |
| Galderma Laboratories, L.P. | $28.37 | 2025 | Nemluvio |
| Alk-Abello, INC | $24.95 | 2021 | |
| Abbvie INC. | $18.42 | 2022 | |
| Tersera Therapeutics LLC | $18.02 | 2025 | Quzyttir |
| Arcutis Biotherapeutics, INC. | $16.15 | 2025 | Zoryve |
| Phadia US INC. | $15.64 | 2023 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Gc Biopharma USA, INC. | $14.41 | 2025 | Alyglo |
| Greer Laboratories, INC. | $13.35 | 2024 | Palforzia |
| Teva Pharmaceuticals USA, INC. | $13.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.